U.S. Markets closed

Amarin publishes additional marker data from MARINE, ANCHOR Phase 3 trials

Amarin announced that additional data from its pivotal MARINE and ANCHOR Phase 3 clinical trials are now available electronically through PubMed and are expected to be published in the print issue of the American Journal of Cardiovascular Drugs in February. The publication reports the effects of Vascepa capsules, alone and in combination with statin therapies, on inflammatory markers associated with cardiovascular disease and atherosclerosis in hypertriglyceridemic patients. In addition to the previously reported favorable lipid effects of Vascepa on hypertriglyceridemic patients in the MARINE and ANCHOR studies, this newly published analysis of these studies shows that Vascepa 4g/day significantly decreased levels of several inflammatory markers relative to placebo, including oxidized low-density lipoprotein, lipoprotein-associated phospholipase A2, and high sensitivity C-reactive protein.